Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths

被引:18
|
作者
Kropp, Peter A. [1 ]
Bauer, Rosemary [1 ,2 ]
Zafra, Isabella [1 ,3 ]
Graham, Carina [1 ,4 ]
Golden, Andy [1 ]
机构
[1] NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA
[2] Northwestern Univ, Driskill Grad Program, Chicago, IL 60611 USA
[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[4] UCL, Inst Child Hlth, London, England
关键词
C; elegans; Disease modeling; Drug screens; Genetic screens; Patient-specific alleles; SPINAL MUSCULAR-ATROPHY; SURVIVAL-MOTOR-NEURON; KSR-1 GENE ENCODES; C-ELEGANS; PLASTIN; PROTEIN; MUTATIONS; NALCN; TOXICITY; CHANNEL;
D O I
10.1242/dmm.049010
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundation and provide the opportunity for understanding their mechanisms and phenotypes, as well as potential treatments. One strategy for effectively and efficiently studying rare diseases is using genetically tractable organisms to model the disease and learn about the essential cellular processes affected. Beyond investigating dysfunctional cellular processes, modeling rare diseases in simple organisms presents the opportunity to screen for pharmacological or genetic factors capable of ameliorating disease phenotypes. Among the small model organisms that excel in rare disease modeling is the nematode Caenorhabditis elegans. With a staggering breadth of research tools, C. elegans provides an ideal system in which to study human disease. Molecular and cellular processes can be easily elucidated, assayed and altered in ways that can be directly translated to humans. When paired with other model organisms and collaborative efforts with clinicians, the power of these C. elegans studies cannot be overstated. This Review highlights studies that have used C. elegans in diverse ways to understand rare diseases and aid in the development of treatments. With continuing and advancing technologies, the capabilities of this small round worm will continue to yield meaningful and clinically relevant information for human health.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Repurposing strategies for tropical disease drug discovery
    Klug, Dana M.
    Gelb, Michael H.
    Pollastri, Michael P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (11) : 2569 - 2576
  • [22] Modeling Molecular and Cellular Aspects of Human Disease Using the Nematode Caenorhabditis elegans
    Gary A Silverman
    Cliff J Luke
    Sangeeta R Bhatia
    Olivia S Long
    Anne C Vetica
    David H Perlmutter
    Stephen C Pak
    [J]. Pediatric Research, 2009, 65 : 10 - 18
  • [23] Modeling Molecular and Cellular Aspects of Human Disease Using the Nematode Caenorhabditis elegans
    Silverman, Gary A.
    Luke, Cliff J.
    Bhatia, Sangeeta R.
    Long, Olivia S.
    Vetica, Anne C.
    Perlmutter, David H.
    Pak, Stephen C.
    [J]. PEDIATRIC RESEARCH, 2009, 65 (01) : 10 - 18
  • [24] Mitochondrial bioenergetics and disease in Caenorhabditis elegans
    Dancy, Beverley M.
    Sedensky, Margaret M.
    Morgan, Philip G.
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2015, 20 : 198 - 228
  • [25] Molecular modeling of mechanotransduction in the nematode Caenorhabditis elegans
    Tavernarakis, N
    Driscoll, M
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, 1997, 59 : 659 - 689
  • [26] Computational modeling of Caenorhabditis elegans vulval induction
    Sun, Xiaoyun
    Hong, Pengyu
    [J]. BIOINFORMATICS, 2007, 23 (13) : I499 - I507
  • [27] The Role of Alternative Toxicological Trials in Drug Discovery Programs. The Case of Caenorhabditis elegans and Other Methods
    Goethel, Gabriela
    Augsten, Lucas Volnei
    das Neves, Gustavo Machado
    Goncalves, Itamar Luis
    Silveira de Souza, Joao Pedro
    Garcia, Solange Cristina
    Eifler-Lima, Vera Lucia
    [J]. CURRENT MEDICINAL CHEMISTRY, 2022, 29 (32) : 5270 - 5288
  • [28] Zebrafish: From disease modeling to drug discovery
    Rubinstein, AL
    [J]. CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2003, 6 (02) : 218 - 223
  • [29] Industrializing neglected and rare disease drug discovery and development
    Lingerfelt, Mary
    Zorn, Kimberley
    Hupcey, Maggie
    Ekins, Sean
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [30] Introduction to special issue on rare disease drug discovery
    Schmidt, Darby
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 92